Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy

Marrone, Luiz Carlos Porcello; Marrone, Bianca Fontana; Pascoal, Tharick A.; Schilling, Lucas Porcello; Soder, Ricardo Bernardi; Ferreira, Sheila; Gadonski, Giovani; Costa, Jaderson Costa da

doi:10.1155/2013/306983

Cited by 11 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…By the way, it was identified 34 patients (eighteen were pregnant or in puerperium period). The other group was composed by four patients with lupus, four with neoplasia in chemotherapy, 9 , 19 four with glomerulonephritis, two patients with hypertension, two patients in use of Tacrolimus after renal transplantation, two patients with Hemolitic Uremic syndrome, one after scorpion sting and one patient with alteration of renal function. 20 …”

Section: Resultsmentioning

confidence: 99%

Posterior reversible encephalopathy syndrome: differences between pregnant and non-pregnant patients

et al. 2014

Self Cite

View full text Add to dashboard Cite

Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiologic entity not yet understood, that presents with transient neurologic symptoms and particular radiological findings. Few papers show the differences between pregnant and non-pregnant patients. We review the cases of 38 women diagnosed with PRES, in order to find significant differences between pregnant (18) and non-pregnant (20) patients. We found differences among the age of patients (25.83 years old in pregnant and 29.31 years old in non pregnant; P=0.001); in the mean of highest systolic blood pressure, that was higher in non-pregnant group (185:162 mmHg; P=0.121); and in creatinine levels that was higher in non-pregnant group (3.47:1.04 mg/dL; P=0.001). To our knowledge, just a few papers analyzed whether PRES syndrome presented in the same way in pregnant and non-pregnant patients. The differences and the possible pathophisiology of this syndrome still remain enigmatic.

show abstract

Section: Resultsmentioning

confidence: 99%

Posterior reversible encephalopathy syndrome: differences between pregnant and non-pregnant patients

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…FOLFOX-induced hyperammonemic encephalopathy has been previously described but is limited to case reports. A wide array of clinical presentations with varying severity and acuity has been reported, and the onset of symptoms after the start of chemotherapy typically was subacute, ranging from nine to 23 days [4][5][6].…”

Section: Discussionmentioning

confidence: 99%

A Case of Acute Encephalopathy After the Initiation of FOLFOX Chemotherapy in a Patient With Colon Cancer

Kim¹,

Lio²,

Henderson³

et al. 2023

Cureus

View full text Add to dashboard Cite

Acute encephalopathy is a change in the level of consciousness where the underlying etiology can be difficult to diagnose, and thus, difficult to treat, especially in the context of multi-organ diseases. We report a case of acute encephalopathy in a patient with end-stage renal disease (ESRD) on hemodialysis, chronic hypotension, and a recent diagnosis of colon cancer who presented shortly after initiation of FOLFOX, a chemotherapy regimen for treatment of colorectal cancer comprised of folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin (eloxatin). We present a systematic approach to elucidate ambiguous causes of toxicmetabolic encephalopathy.

show abstract

“…Regarding encephalopathy after FOLFOX chemotherapy, posterior reversible encephalopathy, Wernike's encephalopathy, and hyperammonemic encephalopathy have been reported [ 2 3 ]. With our patient, we could reach the conclusion of chemotherapy-induced hyperammonemic encephalopathy because the patient's brain images did not show abnormal findings, and there is no abnormal laboratory findings to indicate altered mentality except for markedly increased ammonia levels.…”

Section: Discussionmentioning

confidence: 99%

Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy

Hong

Moon

et al. 2016

Ann Surg Treat Res

View full text Add to dashboard Cite

5-Fluorouracil (5-FU) based chemotherapy has been commonly used to treat metastatic or advanced colon cancer as an adjuvant chemotherapy. Although the side effects of 5-FU such as gastrointestinal problems and neutropenia and thrombocytopenia are common, not many cases of 5-FU related encephalopathy are reported. Hyperammonemic encephalopathy is a rare central nervous system toxicity following 5-FU chemotherapy manifesting as altered mental status with elevated ammonia levels with no radiologic abnormality. We report one case of 5-FU induced hyperammonemic encephalopathy occurring after Folfox4 (oxaliplatin, folinic acid and 5-fluorouracil) chemotherapy in a colon cancer patient who presented with confused mental status soon after the chemotherapy and review the 5-FU related encephalopathy.

show abstract

Posterior Reversible Encephalopathy Syndrome Associated with FOLFOX Chemotherapy

Cited by 11 publications

References 9 publications

Posterior reversible encephalopathy syndrome: differences between pregnant and non-pregnant patients

Posterior reversible encephalopathy syndrome: differences between pregnant and non-pregnant patients

A Case of Acute Encephalopathy After the Initiation of FOLFOX Chemotherapy in a Patient With Colon Cancer

Acute hyperammonemic encephalopathy after 5-fluorouracil based chemotherapy

Contact Info

Product

Resources

About